Science & Technology
NEUMANN has a new approach: personalized risk assessment for every women.
The CONFIDENCE™ Marker can establish the risk of every patient for cervical dysplasia. Based on the patient’s age and the epigenetic marker test result NEUMANN’s proprietary algorithm can calculate the risk for a CIN2+ (moderate cervical squamous intraepithelial neoplasia or worse) condition.
The maps were created after testing baseline visit samples of over 6,000 women aged between 20 and 60. The risk levels represent the ratio of CIN2+ cases versus those which are negative or presumed negative. The figure below is a risk map showing the level of risk attributed to the combinations of age and the methylation index of hrHPV positive women.
It is visible that already a low methylation index (50) of the POU4F3 gene means high risk especially for the ages 25 to 40. A similar level of methylation above the age of 50 suggests a much lower level of risk. For example a methylation index of 50 at age 32 means a significantly higher level of risk than at age 52: 13% versus 2.9%, respectively. It is important to note that the majority of the 1,595 cases tested (over 75%) had <5% risk for underlying CIN2+; and less than 4% of the samples carried >40% risk.
In contrast, on the figure below the risk assessment map for hrHPV negative women shows the very low risk this patient group has for CIN2+.
This risk assessment method is a unique and useful way of evaluating samples – especially those which have a negative or borderline cytology result, because the CONFIDENCE™ Marker can provide an independent evaluation helping doctors to manage patients better.
Learn more about the CONFIDENCE™ products.